Sunflower’s Cross-Industry Acquisition: Opportunities and Challenges in the Semiconductor Sector
On the evening of September 7, 2025, Sunflower (300111.SZ) announced that the company is planning to acquire a controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. (hereinafter referred to as “Xipu Materials”) and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. (hereinafter referred to as “Beid Pharmaceutical”) through the issuance of shares and/or cash payment, while also planning to raise supporting funds. This news, once released, stirred the capital market like a stone thrown into a lake.
1. Background and Motivation of the Transaction
Performance Pressure, Seeking Breakthrough
Sunflower’s current main business focuses on the pharmaceutical field, with leading products including anti-infection drugs, cardiovascular drugs, and digestive system drugs, possessing a relatively complete industrial chain for anti-infection and antihypertensive drugs. However, in the first half of 2025, the company’s performance showed a significant decline: operating income was 144 million yuan, a year-on-year decrease of 8.33%; net profit attributable to shareholders was 1.1607 million yuan, a year-on-year decrease of 35.68%; and net profit excluding non-recurring items was only 44,800 yuan, a year-on-year decrease of 94.46%. The main reasons for the decline in performance include a decrease in market demand for formulated drugs, a sharp drop in sales of certain anti-infection products, lower prices of competing products, and the impact of reduced overseas orders on the raw material drug business. In this context, the company urgently needs to find new business growth points to improve its performance.
Attractive Industry Prospects, Layout of New Tracks
Xipu Materials is a supplier of electronic materials in the semiconductor market, dedicated to developing advanced materials for the semiconductor market, with products including electronic-grade gases such as hexafluorobutadiene and trifluoride, as well as precursors like bis(t-butylamino)silane. In recent years, the semiconductor industry has been booming, especially under the backdrop of domestic substitution, with semiconductor materials being a key foundation of the industry, leading to continuous growth in market demand and broad development prospects. Sunflower’s cross-industry acquisition aims to seize the development opportunities in the semiconductor industry, open up new business tracks, and achieve diversified development.
2. Analysis of the Transaction Plan
Targets and Methods of Acquisition
This transaction involves two target companies. For Beid Pharmaceutical, in which it already holds a 60% stake, Sunflower intends to acquire the remaining 40% equity from Shaoxing Sunflower Investment Co., Ltd., controlled by actual controller Wu Jianlong, through the issuance of shares. If the transaction is completed, Beid Pharmaceutical will become a wholly-owned subsidiary of Sunflower, which will help the company further integrate pharmaceutical business resources, enhance its control over Beid Pharmaceutical, and strengthen the competitiveness of its pharmaceutical main business. For Xipu Materials, Sunflower plans to acquire the controlling stake held by Shanghai Xipu Technology Co., Ltd. through the issuance of shares and/or cash payment, thereby entering the semiconductor materials field and expanding the company’s business boundaries.
Supporting Fundraising
To ensure the smooth progress of the acquisition and subsequent business integration and development, Sunflower plans to raise supporting funds. The use of these funds may include paying acquisition consideration, supplementing the target company’s working capital, investing in new business research and development, and market expansion, which will help alleviate the company’s financial pressure, optimize its capital structure, and provide financial support for future development.
3. Potential Impact Analysis
Strategic Level
If the acquisition is successful, Sunflower will achieve a cross-industry transition from the pharmaceutical industry to the semiconductor materials field, establishing a dual main business development pattern of “pharmaceuticals + semiconductor materials,” diversifying operational risks, enhancing the company’s ability to withstand market fluctuations, and increasing the overall strategic value and market competitiveness of the company, opening up new imaginative space for future development.
Financial Level
In the short term, the acquisition may increase the company’s financial burden, such as rising debt levels and increased financial expenses. However, in the long term, if effective integration can be achieved, the high growth potential of Xipu Materials is expected to bring new profit growth points to the company, enhancing its overall profitability and asset quality. Additionally, achieving full control over Beid Pharmaceutical may also, to some extent, increase the company’s net profit attributable to shareholders. However, if the performance of the acquired companies does not meet expectations or if issues arise during the integration process, the company may face goodwill impairment risks, adversely affecting its financial condition.
Market Level
After the announcement, on September 5, Sunflower’s stock price surged by more than 14% during the afternoon session, closing with an increase of 11.96%, reflecting the market’s optimistic expectations for this acquisition. If the acquisition is successfully completed, it will enhance the company’s visibility and attractiveness in the capital market, helping the company gain more resources and opportunities in future financing and cooperation. However, if the acquisition fails or subsequent developments do not meet expectations, it may raise doubts about the company, leading to a decline in stock price.
4. Risk Warning
Transaction Approval Risks
This transaction is still in the planning stage and needs to be submitted to the company’s board of directors and shareholders’ meeting for review, and must be approved by regulatory agencies before it can be officially implemented, posing the risk that the transaction plan may not pass the relevant reviews and approvals.
Integration Risks
The pharmaceutical and semiconductor materials sectors belong to two different industries, with significant differences in business models, technology development, market channels, and corporate culture. After the acquisition is completed, the company will face challenges in business integration, personnel merging, and technology collaboration. If integration is not handled properly, the expected synergies may not be realized, affecting the company’s development.
Market and Technology Risks
The semiconductor materials industry is characterized by rapid technological updates and intense market competition. Xipu Materials needs to continuously invest in research and development to maintain technological leadership and product competitiveness. If market demand changes in the future, or if the company falls behind competitors in technology development and market expansion, it may lead to a decline in the performance of the target company, thereby affecting Sunflower’s overall performance.
The acquisition planned by Sunflower is a significant strategic transformation attempt in the face of performance pressure. While it contains enormous development opportunities, it also comes with numerous risks and challenges. Investors need to closely monitor the progress of the transaction and subsequent integration, making cautious investment decisions. For the company, how to achieve successful transformation and collaborative development in a complex market environment and industry differences will be an important issue in the future.